Download PDF
Synlett 2018; 29(01): 71-74
DOI: 10.1055/s-0036-1588561
letter
© Georg Thieme Verlag Stuttgart · New York

Palladium-Catalyzed Cross-Coupling of 1,3,4-Oxadiazoles and Styrenes: An Efficient Method to Synthesize 2-Alkenyl-1,3,4- Oxadiazoles§

N. Salvanna*
a   Osmania University Postgraduate College, Narsapur, Medak, Telangana 502313, India
,
P. Raghavendar Reddy
b   Natural Products Chemistry Division, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India   Email: biswanathdas@yahoo.com
,
Biswanath Das*
b   Natural Products Chemistry Division, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India   Email: biswanathdas@yahoo.com
› Author Affiliations
Further Information

Publication History

Received: 23 June 2017

Accepted after revision: 31 July 2017

Publication Date:
25 August 2017 (online)

    Permissions and Reprints All articles of this category


§ Part 240 in the Series ‘Studies on Novel Synthetic Methodologies’

Abstract

2-Alkenyl-1,3,4-oxadiazole derivatives have been prepared by cross-coupling of 1,3,4-oxadiazoles with styrenes by using palladium(II) trifluoroacetate [Pd(TFA)2] as a catalyst, 1,10-phenanthroline as a ligand, silver trifluoroacetate as an oxidant, and toluene as a solvent. The products were formed in high yields and no byproducts were detected.

Keywords

oxadiazoles - styrenes - palladium catalysis - cross-coupling - silver trifluoroacetate - alkenylation
 

  • References and Notes

  • 1 Leung D. Du W. Hardouin C. Cheng H. Hwang I. Cravatt BF. Boger DL. Bioorg. Med. Chem. Lett. 2005; 15: 1423
    CrossrefSearch in Google Scholar
  • 2 Singh S. Sharma LK. Saraswat A. Siddiqui IR. Kheri HK. Singh RK. P. RSC Adv. 2013; 3: 4237.
    CrossrefSearch in Google Scholar
  • 7 Husain A. Ajmal M. Acta Pharm. (Zagreb, Croatia) 2009; 59: 223
    CrossrefPubMedSearch in Google Scholar
  • 8 Johns BA. WO 2004101512, 2004
  • 9 Kagthara PR. Shah NS. Doshi RK. Parekh HH. Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. 1999; 38: 572
    Search in Google Scholar
  • 11 Gaonkar SL. Rai KM. L. Prabhuswamy B. Eur. J. Med. Chem. 2006; 41: 841
    CrossrefPubMedSearch in Google Scholar
  • 12 Shirote PJ. Bhatia MS. Chin. J. Chem. 2010; 28: 1429
    CrossrefSearch in Google Scholar
  • 13 Yale HI. Losee K. J. Med. Chem. 1966; 9: 478
    CrossrefPubMedSearch in Google Scholar
  • 14 I-Ansari SL. Sarhan TZ. Aly I. Soliman GA. Bull. Fac. Pharm. (Cairo University) 1993; 31: 203
    Search in Google Scholar
    • 16a 2-Alkenyl- 1,3,4-oxadiazoles 3a–q; General Procedure A 10 mL round-bottomed flask was charged with the appropriate 1,3,4-oxadiazole 1 (0.5 mmol), styrene 2 (1.5 mmol), Pd(TFA)2 (10 mol%), 1,10-phen (10 mol%), AgTFA (2.0 equiv), and toluene (3 mL), and the mixture was stirred at 120 °C under N2 for 24 h until the starting materials were consumed (TLC). The mixture was then allowed to cool and extracted with EtOAc (2 × 10 mL). The organic extracts were combined, dried ­(Na2SO4), filtered, and concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 60 × 120 mesh, EtOAc-hexane 10:90). 2-(4-Methoxyphenyl)-5-[(E)-styryl]-1,3,4-oxadiazole (3a)15b White solid; yield: 113 mg (82%); mp 135–137 °C; IR (KBr): 2382, 1609, 1493, 1449, 1257 cm–1. 1H NMR (200 MHz, CDCl3): δ = 8.07 (d, J = 8.0 Hz, 2 H), 7.65–7.52 (m, 3 H), 7.48–7.31 (m, 4 H), 7.02 (d, J = 14.0 Hz, 2 H), 3.90 (s, 3 H). 13C NMR (50 MHz, CDCl3): δ = 162.9, 138.8, 135.1, 130.0, 129.1, 128.9, 127.8, 116.3, 114.8, 110.2, 55.7. ESIMS: m/z 279 [M + H]+; HRMS (ESI): m/z [M + H]+ calcd for C17H15N2O2: 279.1133; found: 279.1136. 2-[(E)-Styryl]-5-(4-tolyl)-1,3,4-oxadiazole (3c)15b White solid; yield: 110 mg (85%); mp 127–129 °C; IR (KBr): 2378, 1642, 1492, 1443, 1258 cm–1. 1H NMR (200 MHz, CDCl3): δ = 7.99 (d, J = 8.0 Hz, 2 H), 7.60–7.52 (m, 3 H), 7.41–7.28 (m, 5 H), 7.05 (d, J = 14.0 Hz, 1 H), 2.42 (s, 3 H). 13C NMR (50 MHz, CDCl3): δ = 164.1, 142.3, 138.8, 134.9, 130.1, 130.0, 129.2, 127.6, 126.9, 121.1, 110.0, 21.2. ESIMS: m/z = 263 [M + H]+; HRMS (ESI): m/z [M + H]+ calcd for C17H15N2O: 263.1184; found: 263.1185. 2-[(E)-Styryl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazole (3e)15b White solid; yield: 128 mg (82%); mp 146–148 °C; IR (KBr): 2382, 1643, 1518, 1329, 1163 cm–1. 1H NMR (200 MHz, CDCl3): δ = 8.26 (d, J = 8.0 Hz, 2 H), 7.79 (d, J = 8.0 Hz, 2 H), 7.64–7.52 (m, 3 H), 7.46–7.38 (m, 3 H), 7.09 (d, J = 14.0 Hz, 1 H). 13C NMR (50 MHz, CDCl3): δ = 162.9, 139.9, 134.4, 130.1, 129.2, 127.5, 127.2, 126.1, 109.2. ESIMS: m/z 317 [M + H]+; HRMS (ESI): m/z [M + H]+ calcd for C17H12F3N2O: 317.0901; found: 317.0904. 2-[(E)-2-Biphenyl-4-ylvinyl]-5-(4-tolyl)-1,3,4-oxadiazole (3g)15b White solid; yield: 135 mg (80%); mp 150–152 °C; IR (KBr): 2394, 1638, 1490, 1410, 1268 cm–1. 1H NMR (200 MHz, CDCl3): δ = 8.01 (d, J = 8.0 Hz, 2 H), 7.68–7.57 (m, 7 H), 7.49–7.30 (m, 5 H), 7.10 (d, J = 14.0 Hz, 1 H), 2.43 (s, 3 H). 13C NMR (50 MHz, CDCl3): δ = 164.5, 142.8, 142.5, 140.2, 138.4, 133.9, 129.9, 129.1, 128.0, 127.9, 127.8, 127.0, 121.1, 110.0, 21.8. ESIMS: m/z 339 [M + H]+; HRMS (ESI): m/z [M + H]+ calcd for C23H19N2O: 339.1497; found: 339.1511. (E)-2-[2-(Biphenyl-4-yl)vinyl]-5-(4-methoxyphenyl)-1,3,4-oxadiazole (3h)15b White solid; yield: 155 mg (88%); mp 164–166 °C; IR (KBr): 2394, 1610, 1494, 1451, 1256 cm–1. 1H NMR (200 MHz, CDCl3): δ = 8.05 (d, J = 8.0 Hz, 2 H), 7.72–7.54 (m, 7 H), 7.49–7.30 (m, 4 H), 7.10 (d, J = 14.0 Hz, 1 H), 7.01 (d, J = 8.0 Hz, 1 H), 3.91 (s, 3 H). 13C NMR (50 MHz, CDCl3): δ = 162.7, 142.9, 140.0, 137.9, 134.1, 128.9, 128.8, 128.0, 127.9, 127.7, 127.1, 116.6, 114.5, 109.9, 55.2. ESIMS: m/z 355 [M + H]+; HRMS (ESI): m/z [M + H]+ calcd for C23H19N2O2: 355.1446; found: 355.1460.